🇺🇸 FDA
Pipeline program

JNJ-63723283, JNJ-42756493, JNJ-42756493, JNJ-42756493

SOGUG2020IEC(VEJ)11

Phase 2 small_molecule active

Quick answer

JNJ-63723283, JNJ-42756493, JNJ-42756493, JNJ-42756493 for Muscle-invasive bladder cancer (MIBC) is a Phase 2 program (small_molecule) at Tour Hekla with 1 ClinicalTrials.gov record(s).

Program details

Company
Tour Hekla
Indication
Muscle-invasive bladder cancer (MIBC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials